Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and long-term protection of Engerix-B Junior in newborns of HBeAg+ and HBsAg+ mothers
2011-002629-23Phase 4
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of hepatitis B vaccine recombinant in hepatitis B (HBV) (2 arms), sponsored by GSK. Primary endpoints: anti-HBs seropositivity rate, anti-HBs seroprotection rate and 1 more.
02
Drugs
hepatitis B vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2011-002629-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002629-23.